Business
NTRR Joint Venture Partner Prepares to Launch BeKind Topicals Brand in Explosive Cannabis Market
NTRR Joint Venture Partner Prepares to Launch BeKind Topicals Brand in Explosive Cannabis Market.
About this update from Neutra Corp.
[{"type":"text","content":"\n \n Neutra Corp. (OTCQB:NTRR) joint venture partner Oceanview Health \n Services Ltd. is making the necessary preparations to debut a new brand \n of cannabis-infused topical products, BeKind Topicals, in markets where \n cannabis is legal and regulated.\n \n \n NTRR formed its joint venture with the Vancouver-based Oceanview last \n month. Oceanview is working on new formulas for cutting-edge topical \n creams, oils, salves, lotions and more that have been infused with \n medicinal cannabis. Major revenues could potentially be derived from \n licensing the brand and its recipes to top distributors in territories \n with regulated medical cannabis marketplaces.\n \n \n The joint venture was formed to capitalize on cannabis topicals’ booming \n popularity among cannabis patients. BeKind Topicals products could soon \n prove useful in treating a wide variety of health issues, such as \n arthritis, muscle soreness, nerve pain and more.\n \n \n “Topicals are undoubtedly one of the fastest-growing segments in the \n North American cannabis industry,” said NTRR CEO Chris Brown. “Our \n partnership with Oceanview has our company well-positioned to succeed in \n the rapidly emerging marketplace. Demand for these products appears to \n be growing by the day wherever cannabis is legal.”\n \n \n In 2016, NTRR plans to deliver many new offerings for cannabis producers \n and consumers alike as the regulated cannabis industry continues to \n swell in the United States, Canada and beyond.\n \n \n About Neutra Corp.\n \n \n As the global cannabis market grows exponentially, it is constantly in \n need of better technologies and products to be more efficient in how \n they grow, what they grow, and how they consume cannabis and its related \n products. From lighting to dosage devices, from pesticide replacements \n to plant enhancers, NTRR is constantly combing the industry for the \n latest and greatest to test, prove and bring to market.\n \n \n By providing a variety of new technologies designed to ensure safer, \n more reliable access to cannabis in approved markets, Neutra Corp. plans \n to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara \n Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: \n XXII). For investing information and performance data, please visit www.neutracor...